

CURRICULUM VITAE
KENNETH JON DORNFELD, PHD, MD

BUSINESS ADDRESS:

The Duluth Clinic, Ltd.¹
400 East Third Street
Duluth, MN 55805

PRIMARY PRACTICE SITE:

The Duluth Clinic, Ltd.¹
dba Essentia Health Duluth Clinic
420 East First Street
Duluth, MN 55805

PRESENT POSITIONS:

2011- Medical Director, Breast Program, Essentia Health Duluth Clinic,
Duluth, MN
2010- Member, Essentia Medical Group-Duluth²
2007- Staff Physician and Section Chair, Department of Radiation/Oncology,
Essentia Health Duluth Clinic, Duluth, MN

MEDICAL STAFF PRIVILEGES:

St. Mary's Medical Center, dba
• Essentia Health St. Mary's Medical Center
SMDC Medical Center, dba
• Essentia Health Duluth

PAST POSITIONS:

2002-2007 Assistant Professor, Department of Radiation Oncology, The
University of Iowa, Iowa City, IA
2000-2002 Chief of Service, Department of Radiation Oncology, Veterans Affairs
Hospital, Ann Arbor, MI
1999-2002 Staff Physician, Department of Radiation Oncology, Veterans
Administration Medical Center, Ann Arbor, MI
1999-2002 Staff Physician, Department of Radiation Oncology, University of
Michigan Medical School, Ann Arbor, MI
1998-1999 Chief Resident, Department of Radiation Oncology, University of
Michigan, Ann Arbor, MI

CERTIFICATION:

1999-2019 American Board of Medical Specialties, Radiology

LICENSURE:

Minnesota

¹ This facility is a wholly owned subsidiary of Essentia Health. See attached "Essentia Health Facilities". The Essentia Institute of Rural Health, a wholly owned corporation of Essentia Health, is assigned oversight of research and education for Essentia Health.

² The Essentia Medical Group was formed to provide a common practice environment for all physicians and credentialed providers within Essentia Health.

TEACHING EXPERIENCE:

1. University of Michigan, Guest Lecturer, Graduate Course in Radiobiology, 1999-2000
2. The University of Iowa, Co-instructor, 077:103 Radiation Biology (4 s.h.), Free Radical and Radiation Biology Program, 2002-2006
3. The University of Iowa, Invited Lecturer, *Strategies of anticancer chemotherapy*, 077:288 Molecular and Cellular Biology of Cancer (3 s.h.), Free Radical and Radiation Biology Program, 2003, 2005, 2007
4. The University of Iowa, Co-Instructor, 672:803 Radiobiology for the Radiation Therapist (12 s.h.), Department of Radiation Oncology, 2003-2007
5. The University of Iowa, Course Director, 077:207, Seminars in Radiation Biology, 2004-2007

EDUCATION:

1991-1993	University of Minnesota, MD, Minneapolis, MN
1986-1991	University of Minnesota, PhD Biochemistry, Minneapolis, MN
1984-1986	University of Minnesota, Minneapolis, MN
1980-1984	University of Chicago, BA, Chicago, IL (with honors)

POSTGRADUATE TRAINING:

1994-1999	University of Michigan, Radiation Oncology Resident, Ann Arbor, MI
1993-1994	Hennepin County Medical Center, Transitional Internship, Minneapolis, MN

ACADEMIC APPOINTMENTS

2007-	University of Minnesota-Duluth Medical School, Adjunct Assistant Professor, Department of Biochemistry and Molecular Biology, Duluth, MN
2002-2007	The University of Iowa, Assistant Professor, Department of Radiation Oncology, Iowa City, IA
1999-2002	University of Michigan, Lecturer, Radiation Oncology

HONORS/AWARDS:

2010	Duluth Clinic Researcher of the Year Award
2000-2001	Teacher of the Year Award, Department of Radiation Oncology, University of Michigan
2000	Invited Participant, Radiation Research Program Young Investigators Workshop sponsored by the National Cancer Institute
1999	Chief Resident, Department of Radiation Oncology, University of Michigan
1989	Cyrus P. Barnum, Jr. Memorial Teaching Fellowship, Department of Biochemistry
1984	Graduated With Honors, University of Chicago

PROFESSIONAL MEMBERSHIPS AND SOCIETIES:

	Genetics Society of America
	American College of Radiology
2008	Children's Oncology Group
2002-	American Association of Cancer Research
2000-	American Society of Therapeutic Radiology and Oncology

COMMITTEES/ADMINISTRATIVE RESPONSIBILITIES:

Process Improvement Committee Member (Radiation Oncology)
SMDC Research Committee
SMDC Cancer Center Committee
Miller Dwan Hospital Executive Committee

FUNDED RESEARCH/GRANTS RECEIVED:

1. "Metabolic Approaches to Improve Radiosensitization", SMDC Foundation, 2008-2009
2. "Normal Tissue Hypoxia Following Radiotherapy", SMDC Research Committee, 2008-2009
3. "Mitochondrial Oxidative Stress in Thymineless Death", National Institutes of Health K08), Dornfeld KJ (PI), 2007-2012
4. "The Use of Fluoro-labelled Thymidine in PET Imaging of Head and Neck Cancer", NCI (R21), 2007-2009

CLINICAL TRIALS:

1. Normal Tissue Hypoxia Following Radiotherapy, opened May 1, 2008
2. Investigator Initiated (Dornfeld, PI) Long-term treatment efficacy of parotid-sparing radiation therapy techniques: the University of Iowa Experience (IRB 200508767)
3. Investigator Initiated (Dornfeld, PI) A phase I clinical trial: 2DG + stereotactic radiosurgery (SRS) protocol for treatment of intracranial metastases (IRB 200506744)
4. Investigator Initiated (Dornfeld, co-principal investigator) Biodistribution and radiation dosimetry of F-18 Fluorothymidine (FLT) Imaged with positron emission tomography (PET) in patients with head and neck cancer: a radioactive drug research committee (RDRC) study (IRB 200502799)
5. Investigator Initiated (Dornfeld, co-principal investigator) Assessment of tissue response to hyperbaric oxygen therapy for osteoradionecrosis (IRB 200510757)
6. Investigator Initiated (Dornfeld, PI) Serial blood and salivary sampling for validation of quantitative amifostine assays. (IRB 200406002)
7. Investigator Initiated (Dornfeld, co-principal investigator) Swallowing function in patients after Intensity Modulated Radiation Therapy for head and neck cancer. Does dose delivered to critical structures determine functional outcome? (IRB 200411740; Faculty mentor)
8. Investigator Initiated (Dornfeld, PI) A phase I study of fractionated radiation therapy combined with 2-deoxyglucose for treatment of squamous cell carcinoma of the head and neck (IRB 200311079)
9. Investigator Initiated (Dornfeld, co-principal investigator) Pilot study to evaluate esomeprazole (Nexium) in treating gastro-esophageal reflux in patients with head and neck cancer with prior external beam radiation therapy: a randomized, prospective, placebo-controlled, double-blind study. (IRB 200308067)

10. Investigator Initiated (Dornfeld, co-principal investigator) Development of radiation fibrosis in patients treated with pentoxifylline and vitamin E: a prospective randomized study (IRB 200211003)

PUBLICATIONS - JOURNAL ARTICLES:

1. Dornfeld K, Antifolate response in replication arrest mutants of *Saccharomyces cerevisiae*. *Anticancer Research* 33: in press, 2013
2. Skildum A, Dornfeld K, Wallace K. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. *Breast Cancer Res Treat.* 2011 Oct;129(3):785-97. PMID: 21128112
3. Dornfeld K, Gessert CE, Renier CM, McNaney DD, Urias RE, Knowles DM, et al. Differences in breast tissue oxygenation following radiotherapy. *Radiother Oncol.* 2011;100(2):289-92. Epub 2011/03/02. doi: 10.1016/j.radonc.2011.02.004. PubMed PMID: 21356563.
4. Boles Ponto LL, Menda Y, Dornfeld K, Tewson TJ, Watkins GL, Sunderland J, Graham MM, and Buatti J. Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time. *Cancer Biother Radiopharm* 2010 Jun. 25(3):361-363. 2010/06/29.
5. Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, and Adjei AA. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). *Ann Oncol.* 2010 Jun 21. 2010/06/24.
6. Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, and Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. *Nucl Med Biol* 2010 May. 37(4):433-438. 2010/05/08.
7. Chen CM, Johnson M, Smith BJ, and Dornfeld K. Azidothymidine enhances fluorodeoxyuridine-mediated radiosensitization. *Int J Radiat Oncol Biol Phys.* 2010 Mar 1. 76(3):905-913. 2010/02/18.
8. Simons AL, Mattson DM, Dornfeld K, and Spitz DR. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. *J Cancer Res Ther.* 2009 Sep. 5 Suppl 1:S2-6.
9. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, Sunderland JJ, Graham MM, and Buatti JM. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. *J Nucl Med.* 2009 Jul. 50(7):1028-1035.
10. Mattson DM, Ahmad IM, Dayal D, Parsons AD, Aykin-Burns N, Li L, Orcutt KP, Spitz DR, Dornfeld KJ, Simons AL. Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. *Free Radic Biol Med.* 2009 Jan 15;46(2):232-7.
11. Dornfeld K, Hopkins S, Simmons J, Spitz DR, Menda Y, Graham M, Smith R, Funk G, Karnell L, Karnell M, Dornfeld M, Yao M, and Buatti J. Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy. *Int J Radiat Oncol Biol Phys.* 2008 Jun 1. 71(2):386-392.
12. Simons AL, Fath MA, Mattson DM, Smith BJ, Walsh SA, Graham MM, Hichwa RD, Buatti JM, Dornfeld K, Spitz DR. Enhanced response of human head and neck cancer

- xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. *Int J Radiat Oncol Biol Phys*. 2007 Nov 15;69(4):1222-30.
13. Yao M, Karnell LH, Funk GF, Lu H, Dornfeld KJ, Buatti JM. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2007 Dec 1;69(5):1354-1360. Epub 2007 Aug 8.
 14. Yao M, Hoffman HT, Chang K, Funk GF, Smith RB, Tan H, Clamon GH, Dornfeld KJ, Buatti JM. Is planned neck dissection necessary for head and neck cancer after intensity-modulated radiotherapy? *Int J Radiat Oncol Biol Phys*. 2007 Jul 1;68(3):707-13.
 15. Yao M, Chang K, Funk GF, Lu H, Tan H, Wacha J, Dornfeld KJ, Buatti JM. The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy--the university of Iowa experience. *Int J Radiat Oncol Biol Phys*. 2007 Apr 1;67(5):1332-41.
 16. Dornfeld KJ, Simmons JR, Karnell L, Karnell M, Funk G, Yao M, Wacha J, Zimmerman B, Buatti JM. Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life. *Int J Radiat Oncol Biol Phys*. 2007 Jul 1;68(3):750-7.
 17. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells. *Cancer Res*. 2007 Apr 1;67(7):3364-3370
 18. Yao M, Nguyen T, Buatti JM, Dornfeld KJ, Tan H, Wacha J, Bayouth JE, Clamon GH, Funk GF, Smith RB, Chang K, Hoffman HT. Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research. *Am J Clin Oncol*. 2006 Dec;29(6):606-12.
 19. Allen B, Johnson M, Marsh A, and Dornfeld KJ. Base excision repair of both uracil and oxidatively damaged bases contribute to thymidine deprivation induced radiosensitization. *Int J Radiat Oncol Biol Phys*. 2006, 65;1544-1552.
 20. Lee KC, Hamstra DA, Bullarayasamudram S, Bhojani MS, Moffat BA, Dornfeld KJ, Ross BD, and Rehemtulla A. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. *Gene Therapy*. 2006;13:127-137.
 21. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, and Hoffman HT. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. *Int J Radiat Oncol Biol Phys*. 2005;63:410-421.
 22. El-Deiry M, Funk GF, Nalwa S, Karnell LH, Smith RB, Buatti JM, Hoffman HT, Clamon GH, Graham SM, Trask DK, Dornfeld KJ, and Yao M. Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. *Archives of Otolaryngology--Head & Neck Surgery*. 2005;131:879-885.
 23. Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, Graham SM, Chang K, Dornfeld KJ, Menda Y, and Buatti JM. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. *Int J Radiat Oncol Biol Phys*. 2005;63:991-999.
 24. Yao M, Buatti JM, Dornfeld KJ, Graham MM, Smith RB, Funk GF, and Hoffman HT. Can post-RT FDG PET accurately predict the pathologic status in neck dissection after

- radiation for locally advanced head and neck cancer? In regard to Rogers et al. (*Int J Radiat Oncol Biol Phys* 2004;58:694-697). *Int J Radiat Oncol Biol Phys*. 2005;61:306-307; author reply 307.
25. Dornfeld KJ, and Johnson M. AP endonuclease deficiency results in extreme sensitivity to thymidine deprivation. *Nucleic Acids Research* 2005;33:6644-6653.
 26. Hamstra DA, Lee KC, Tychevicz JM, Schepkin VD, Moffat BA, Chen M, Dornfeld KJ, Lawrence TS, Chenevert TL, Ross BD, Gelovani JT, and Rehemtulla A. The use of ¹⁹F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. *Molecular therapy: the journal of the American Society of Gene Therapy* 2004;10:916-928.
 27. Rehemtulla A, Hamstra DA, Kievit E, Davis MA, Ng EY, Dornfeld KJ, and Lawrence TS. Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy. *Anticancer Research* 2004;24:1393-1399.
 28. Yao M, Graham MM, Hoffman HT, Smith RB, Funk GF, Graham SM, Dornfeld KJ, Skwarchuk M, Menda Y, and Buatti JM. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2004;59:1001-1010.
 29. Yao M, Graham MM, Smith RB, Dornfeld KJ, Skwarchuk M, Hoffman HT, Funk GF, Graham SM, Menda Y, and Buatti JM. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. *Int J Radiat Oncol Biol Phys*. 2004;60:1410-1418.
 30. Yao M, Dornfeld KJ, and Buatti JM. In regard to Lee et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. (*Int J Radiat Oncol Biol Phys* 2003;57:49-60). *Int J Radiat Oncol Biol Phys*. 2004;58:1639; author reply 1639-1640.
 31. Nussenbaum B, Rutherford RB, Teknos TN, Dornfeld KJ, and Krebsbach PH. Ex vivo gene therapy for skeletal regeneration in cranial defects compromised by postoperative radiotherapy. *Human Gene Therapy* 2003;14:1107-1115.
 32. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A, and Lawrence TS. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. *Gene Therapy* 2002;9:844-849.
 33. Dornfeld KJ, and Lawrence TS. A predisposition supposition for glioma. *Journal of the National Cancer Institute* 2001;93:1512-1513.
 34. Radany EH, Dornfeld KJ Sanderson RJ, Savage MK, Majumdar A, Seidman MM, and Mosbaugh DW. Increased spontaneous mutation frequency in human cells expressing the phage PBS2-encoded inhibitor of uracil-DNA glycosylase. *Mutation Research* 2000;461:41-58.
 35. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, and Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. *The Journal of Clinical Endocrinology and Metabolism* 1997;82:3187-3191.
 36. Dornfeld KJ, and Livingston DM. Plasmid recombination in a rad52 mutant of *Saccharomyces cerevisiae*. *Genetics* 1992;131:261-276.

37. Dornfeld KJ, and Livingston DM. Effects of controlled RAD52 expression on repair and recombination in *Saccharomyces cerevisiae*. *Molecular and Cellular Biology* 1991;11:2013-2017.
38. Ahn BY, Dornfeld KJ, Fagrelus TJ, and Livingston DM. Effect of limited homology on gene conversion in a *Saccharomyces cerevisiae* plasmid recombination system. *Molecular and Cellular Biology* 1988;8:2442-2448.

BOOK CHAPTERS:

1. Dornfeld KJ and Menda Y. Functional imaging in the assessment of normal tissue injury following radiotherapy. In: Spitz DR, Dornfeld KJ, Krishnan K and Guis D, *Oxidative Stress in Cancer Biology and Therapy* New York, NY, USA Humana Press 2012
1. El-Deiry M, Trask DK, Hoffman HH, Dornfeld KJ. Carcinoma of the larynx. In: Genden EM, Varvares MA. *Head and Neck Cancer: An Evidence Based Team Approach*. New York, NY, USA: Thieme Publishing Company, 2008.
2. Dornfeld KJ, Buatti J. Biologic modifiers and IMRT. In: Mundt AJ, Roeske JC, eds. *Intensity Modulated Radiation Therapy: A Clinical Perspective, Volume 1*. Hamilton, Ontario, Canada: BC Decker, 2005:615-621.

ABSTRACTS PUBLISHED:

1. Dornfeld K, Gessert C, Renier C, McNaney D, Urias R, Knowles D, Beauduy J, Widell S and McDonald B. Changes in breast tissue oxygenation following radiotherapy. *Int J Radiat Oncol Biol Phys*. 2009; 75(3):S209
2. Yao M, Bayouth JE, Wacha H, Dornfeld KJ, and Buatti JM. Intensity modulated radiotherapy for oral cavity cancer. *Int J Radiat Oncol Biol Phys*. November 2006; 66(3):S431.
3. Radany EH. Dornfeld KJ. Distinct roles of uracil-DNA base excision repair in fluoropyrimidine-mediated radiosensitization and direct cytotoxicity in human tumor cells. *Int J Radiat Oncol Biol Phys*. October 2005, 63: S482-S483.
4. Simmons JR, Dornfeld KJ, Karnell L, Karnell M, Funk G, Yao M, Wacha J, and Zimmerman B. Radiation doses to structures within and adjacent to the larynx are correlated with long term diet and speech related quality of life. *Int J Radiat Oncol Biol Phys*. 2005;63:S132-S132.
5. Yao M, Nguyen T, Dornfeld KJ, Tan H, Wacha J, Bayouth JE, and Buatti JM. Prognostic significance of FDG PET for head and neck cancer treated with IMRT. *Int J Radiat Oncol Biol Phys*. 2005;63:S149-S150.
6. Buatti J, Yao M, Dornfeld KJ, Skwarchuk M, Hoffman HT, Funk GF, Smith RB, Graham SM, Menda Y, and Graham MM. Efficacy of IMRT in head and neck cancer as monitored by post-RT PET scans. *Int J Radiat Oncol Biol Phys*. 2003;57:S305.
7. Yao M, Buatti J, Dornfeld KJ, Skwarchuk M, Menda Y, Graham MM, Smith RB, Graham SM, Funk GF, and Hoffman HT. Is neck dissection necessary when post-radiation PET is negative after radiation treatment for locally advanced head and neck cancer? *Int J Radiat Oncol Biol Phys*. 2003;57:S244-245.
8. Chung TS, Dornfeld KJ, and Rehemtulla A. Optimizing viral dependent enzyme prodrug therapy using cytosine deaminase ASTRO research fellowship. *Int J Radiat Oncol Biol Phys*. 2000;48(3):187.

PRESENTATIONS AND PROFESSIONAL MEETINGS:

1. Ponto L, Menda Y, Dornfeld K, Tewson T, Watkins G, Sunderland J, Graham M, Buatti J. "Consistency of FLT SUVs in Head and Neck Cancer Over Time". Society of Nuclear Medicine Annual Meeting, Toronto, Canada. June 2009.
2. Skildum AJ, Dornfeld K, and Wallace K. "Troglitazone Increases Oxidative Stress and Sensitizes Antiestrogen Resistant Breast Cancer Cells to Adriamycin". American Association for Cancer Research, "Metabolism and Cancer" Symposium, San Diego CA. September 26, 2009.
3. Dornfeld K, Gessert C, Renier C, McNaney D, Urias R, Knowles D, Beauduy J, Widell S and McDonald B. "Changes in Breast Tissue Oxygenation Following Radiotherapy". ASTRO Annual Meeting, Chicago, IL. November 2009.
4. Dornfeld, KJ, Simons J, Karnell M, Karnell L, Funk G, Yao M, Menda Y, Buatti J, and Dornfeld M. "Increased FDG Uptake in the Larynx after Chemoradiotherapy Correlates with Decreased Functional Outcome Following Chemoradiotherapy for Head and Neck Cancer". Joint ASCO ASTRO HNS Meeting, January 2007.
5. Dornfeld KJ. "Metabolic Opportunities to Enhance Cancer Therapy". Annette Boman Symposium, University of Minnesota-Duluth Medical School, Duluth, MN. November 7, 2007.
6. Simmons JR, Dornfeld, KJ, Karnell L, Karnell M, Funk G, Yao M, Wacha J, and Zimmerman B. "Radiation Doses to Structures Within and Adjacent to the Larynx are Correlated with Long Term Diet and Speech Related Quality of Life". American Society for Therapeutic Radiology and Oncology [ASTRO] 47th Annual Meeting, Denver, CO. 2005.
7. Chen, CM and Dornfeld, KJ. "Azidothymidine (AZT) Enhances Radiosensitization of Fluorodeoxyuridine". American Society for Therapeutic Radiology and Oncology [ASTRO] 47th Annual Meeting, Denver, CO. 2005.
8. Dornfeld, KJ. "The Use of 2-Deoxyglucose in Head and Neck Cancer". Midwest Head and Neck Cancer Retreat, Minneapolis, MN. February 2004.